BioCryst agreed to acquire Astria Therapeutics for $700 million, adding navenibart—a Phase 3 injectable antibody for hereditary angioedema—to its pipeline. Management framed the deal as a bid to challenge larger incumbents by offering comparable efficacy with less frequent dosing that could appeal to patients. The acquisition expands BioCryst’s rare‑disease portfolio and positions the company to commercialize an HAE asset should Phase 3 data and regulatory reviews be favorable.